Idexx Laboratories Inc /De (IDXX) Stock Price & Analysis
Idexx Laboratories Inc /De (IDXX) rose 3.16% to USD 578.89 as of June 9, 2026 at 22:43 UTC, according to Nexqual real-time market data.
IDXX last closed at USD 561.17; the session ranged USD 560.29–581.47 on volume of 418,242 shares. Market capitalization is $45.66B, with a 52-week range of USD 506.91–769.98 (NMS). Source: Nexqual, June 9, 2026 at 22:43 UTC.
Key Statistics (as of June 9, 2026 at 22:43 UTC)
| Price | USD 578.89 |
|---|---|
| Change | ▲ 3.16% (up) |
| Previous Close | USD 561.17 |
| Open | USD 563.55 |
| Day Range | USD 560.29 – 581.47 |
| 52-Week Range | USD 506.91 – 769.98 |
| Volume | 418,242 shares |
| Market Cap | $45.66B |
| Exchange | NMS |
Technical Analysis (IDXX)
Nexqual's technical model rates IDXX "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.01 (neutral) |
| vs SMA50 | Above (USD 563.25) |
| MACD | 1.54 (positive) |
Analyst Ratings (IDXX)
Wall Street analysts rate IDXX "Buy" based on 14 analysts, with a mean price target of USD 709.14 (range USD 470–805), per Nexqual as of June 9, 2026 at 22:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 709.14 |
| High Target | USD 805 |
| Low Target | USD 470 |
| Buy / Hold / Sell | 9 / 5 / 1 |
Earnings (IDXX)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 3.94 |
| Revenue Estimate | $1.20B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 3.47 vs est 3.41 ▲ beat |
| 2025-12-31 | USD 3.08 vs est 2.94 ▲ beat |
| 2025-09-30 | USD 3.4 vs est 3.15 ▲ beat |
| 2025-06-30 | USD 3.63 vs est 3.3 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:43 UTC.
Financials & Fundamentals (IDXX)
| Total Revenue | $4.45B |
|---|---|
| Revenue Growth (YoY) | +14.30% |
| Gross Margin | +62.05% |
| Operating Margin | +31.78% |
| Profit Margin | +24.63% |
| ROE | +72.91% |
| Debt / Equity | 71.04 |
| Current Ratio | 1.12 |
| Total Cash | $200.53M |
| Total Debt | $1.11B |
| Free Cash Flow | $786.84M |
Source: Nexqual, June 9, 2026 at 22:43 UTC.
Financial Health Score (IDXX)
Nexqual rates Idexx Laboratories Inc /De's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 22:43 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 32% |
| Balance Sheet | Solid — $201M cash vs $1.11B debt |
| Cash Flow | Strong — FCF $787M, 18% margin |
| Efficiency | Strong — ROE 73%, ROA 26.5% |
Ownership (IDXX)
| Insider Ownership | +0.22% |
|---|---|
| Institutional Ownership | +96.20% |
| Shares Outstanding | 78.88M |
| Float | 78.58M |
| Short % of Float | +2.93% |
Source: Nexqual, June 9, 2026 at 22:43 UTC.
Leadership (IDXX)
Idexx Laboratories Inc /De is led by Michael G. Erickson (age 51), CEO, President & Director, per Nexqual as of June 9, 2026 at 22:43 UTC.
| CEO, President & Director | Michael G. Erickson (age 51) |
|---|---|
| Executive Chairman | Jonathan J. Mazelsky (age 64) |
| Executive VP, CFO & Treasurer | Andrew Emerson (age 42) |
| Executive Vice President of Global Operations and R & D | Martin Smith (age 57) |
| Senior Vice President of Global Operations | Bob Asmann |
Major Backers & Investors (IDXX)
Notable institutional backers of Idexx Laboratories Inc /De include Invesco, BAMCO Inc., Fundsmith LLP, according to Nexqual as of June 9, 2026 at 22:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 4.29% |
| BAMCO Inc. | 2.07% |
| Fundsmith LLP | 1.86% |
| Morgan Stanley | 1.67% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.66% |
| BlackRock | 11.92% |
| State Street | 5.87% |
| Geode Capital | 3.37% |
| BNY Mellon | 1.91% |
Source: Nexqual, June 9, 2026 at 22:43 UTC.
From Idexx Laboratories Inc /De's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
- It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
- The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
- In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZTS | Zoetis Inc. | USD 82.2 | ▲ 3.47% |
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| ALGN | Align Technology, Inc. | USD 178.1 | ▲ 6.18% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:43 UTC. This page is informational and not investment advice.